LENVATINIB
Manner of administration:Oral
Restriction (Streamlined authority code: 17864)
Indication: Locally advanced or metastatic differentiated thyroid cancer
Treatment phase: Initial treatment
Restriction (Streamlined authority code: 17865)
Indication: Locally advanced or metastatic differentiated thyroid cancer
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 2 | DPMQ: $2,126.84 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Lenvima | |||||
Manner of administration:Oral
Restriction (Streamlined authority code: 17864)
Indication: Locally advanced or metastatic differentiated thyroid cancer
Treatment phase: Initial treatment
Restriction (Streamlined authority code: 17865)
Indication: Locally advanced or metastatic differentiated thyroid cancer
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 2 | Max qty units: 60 | # of repeats: 2 | DPMQ: $4,162.94 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Lenvima | |||||
Manner of administration:Oral
Restriction (Streamlined authority code: 17793)
Indication: Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular
carcinoma
Treatment phase: Initial treatment
Restriction (Streamlined authority code: 18018)
Indication: Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular
carcinoma
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 3 | Max qty units: 90 | # of repeats: 2 | DPMQ: $6,162.93 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Lenvima | |||||
Manner of administration:Oral
Restriction (Streamlined authority code: 17786)
Indication: Stage IV clear cell variant renal cell carcinoma (RCC)
Treatment phase: Initial treatment
Restriction (Streamlined authority code: 17860)
Indication: Stage IV clear cell variant renal cell carcinoma (RCC)
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 2 | Max qty units: 60 | # of repeats: 2 | DPMQ: $4,144.90 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Lenvima | |||||
Manner of administration:Oral
Restriction (Streamlined authority code: 17786)
Indication: Stage IV clear cell variant renal cell carcinoma (RCC)
Treatment phase: Initial treatment
Restriction (Streamlined authority code: 17860)
Indication: Stage IV clear cell variant renal cell carcinoma (RCC)
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 2 | Max qty units: 60 | # of repeats: 2 | DPMQ: $4,162.94 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Lenvima | |||||
Manner of administration:Oral
Restriction (Streamlined authority code: 17943)
Indication: Advanced, metastatic or recurrent endometrial carcinoma
Treatment phase: Initial treatment
Restriction (Streamlined authority code: 18017)
Indication: Advanced, metastatic or recurrent endometrial carcinoma
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 2 | Max qty units: 60 | # of repeats: 2 | DPMQ: $4,162.94 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Lenvima | |||||
Manner of administration:Oral
Restriction (Streamlined authority code: 17943)
Indication: Advanced, metastatic or recurrent endometrial carcinoma
Treatment phase: Initial treatment
Restriction (Streamlined authority code: 18017)
Indication: Advanced, metastatic or recurrent endometrial carcinoma
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 2 | Max qty units: 60 | # of repeats: 2 | DPMQ: $4,144.90 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Lenvima | |||||